• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.

作者信息

Remon J, Soria J-C, Peters S

机构信息

Department of Medical Oncology, Centro Integral Oncológico Clara Campal (HM-CIOCC), Hospital HM Nou Delfos, HM Hospitales, Barcelona, Spain.

University Paris-Saclay and Gustave Roussy Cancer Campus, Villejuif, France.

出版信息

Ann Oncol. 2021 Dec;32(12):1637-1642. doi: 10.1016/j.annonc.2021.08.1994. Epub 2021 Sep 1.

DOI:10.1016/j.annonc.2021.08.1994
PMID:34481037
Abstract
摘要

相似文献

1
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.早期和局部晚期非小细胞肺癌：聚焦诊断、分期、全身及局部治疗的ESMO临床实践指南更新
Ann Oncol. 2021 Dec;32(12):1637-1642. doi: 10.1016/j.annonc.2021.08.1994. Epub 2021 Sep 1.
2
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.早期和局部晚期非小细胞肺癌（NSCLC）：ESMO临床实践指南之诊断、治疗及随访
Ann Oncol. 2013 Oct;24 Suppl 6:vi89-98. doi: 10.1093/annonc/mdt241. Epub 2013 Jul 16.
3
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.早期和局部晚期非小细胞肺癌（NSCLC）：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv1-iv21. doi: 10.1093/annonc/mdx222.
4
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.早期及局部晚期（非转移性）非小细胞肺癌：ESMO临床诊断、治疗及随访实践指南
Ann Oncol. 2010 May;21 Suppl 5:v103-15. doi: 10.1093/annonc/mdq207.
5
2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.第二届 ESMO 肺癌共识会议：早期非小细胞肺癌诊断、治疗和随访共识。
Ann Oncol. 2014 Aug;25(8):1462-74. doi: 10.1093/annonc/mdu089. Epub 2014 Feb 20.
6
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.非小细胞肺癌：ESMO关于诊断、治疗及随访的临床建议
Ann Oncol. 2008 May;19 Suppl 2:ii39-40. doi: 10.1093/annonc/mdn081.
7
Non-small cell lung cancer, version 1.2015.非小细胞肺癌临床实践指南（2015 年版）
J Natl Compr Canc Netw. 2014 Dec;12(12):1738-61. doi: 10.6004/jnccn.2014.0176.
8
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.泛亚地区调整的 ESMO 临床实践指南：局部晚期不可切除的非小细胞肺癌患者管理：一项由 KSMO-ESMO 发起、CSCO、ISMPO、JSMO、MOS、SSO 和 TOS 支持的倡议。
Ann Oncol. 2020 Feb;31(2):191-201. doi: 10.1016/j.annonc.2019.10.026. Epub 2019 Dec 20.
9
Diagnosis and treatment of lung cancer: summary of updated NICE guidance.肺癌的诊断与治疗：英国国家卫生与临床优化研究所（NICE）最新指南总结
BMJ. 2011 Apr 27;342:d2110. doi: 10.1136/bmj.d2110.
10
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.转移性非小细胞肺癌（NSCLC）：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39. doi: 10.1093/annonc/mdu199. Epub 2014 Aug 11.

引用本文的文献

1
Curative intent therapy of stage I-III non-small cell lung cancer: a patient-centered precision approach to assess, measure, and interpret benefits and harms.I-III期非小细胞肺癌的根治性意向治疗：一种以患者为中心的精准方法，用于评估、衡量和解释获益与危害。
J Thorac Dis. 2025 Jul 31;17(7):4473-4500. doi: 10.21037/jtd-2025-213. Epub 2025 Jul 29.
2
Recent Advances in PET and Radioligand Therapy for Lung Cancer: FDG and FAP.肺癌正电子发射断层显像（PET）及放射性配体疗法的最新进展：氟代脱氧葡萄糖（FDG）与成纤维细胞活化蛋白（FAP）
Cancers (Basel). 2025 Aug 1;17(15):2549. doi: 10.3390/cancers17152549.
3
Early-stage resectable non-small cell lung cancer in Hungary.
匈牙利的早期可切除非小细胞肺癌
Pathol Oncol Res. 2025 Jul 28;31:1612152. doi: 10.3389/pore.2025.1612152. eCollection 2025.
4
Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events.晚期非小细胞肺癌双重免疫疗法的真实世界单中心数据分析：疗效、生存率及不良事件
Hum Vaccin Immunother. 2025 Dec;21(1):2542068. doi: 10.1080/21645515.2025.2542068. Epub 2025 Aug 4.
5
Repurposing Rafoxanide: From Parasite Killer to Cancer Fighter.雷复尼特的新用途：从抗寄生虫药到抗癌药。
Biomedicines. 2025 Jul 9;13(7):1686. doi: 10.3390/biomedicines13071686.
6
Imaging features and prognostic significance of immune checkpoint inhibitor-related pneumonitis in NSCLC.非小细胞肺癌中免疫检查点抑制剂相关肺炎的影像学特征及预后意义
BMC Cancer. 2025 Jul 19;25(1):1192. doi: 10.1186/s12885-025-14628-5.
7
Mediastinal staging of nonsmall cell lung cancer: what's new?非小细胞肺癌的纵隔分期：有哪些新进展？
Breathe (Sheff). 2025 Jul 15;21(3):230191. doi: 10.1183/20734735.0191-2023. eCollection 2025 Jul.
8
Evaluation of the efficacy and safety of durvalumab combined with chemotherapy, radiotherapy, or other agents in advanced non-small cell lung cancer: a meta-analysis.度伐利尤单抗联合化疗、放疗或其他药物治疗晚期非小细胞肺癌的疗效和安全性评估：一项荟萃分析
Int J Clin Exp Pathol. 2025 Jun 15;18(6):203-221. doi: 10.62347/BNVX1803. eCollection 2025.
9
A network meta-analysis of efficacy and safety of adjuvant targeted therapy or immunotherapy in non-small cell lung cancer.非小细胞肺癌辅助靶向治疗或免疫治疗疗效与安全性的网状Meta分析
Sci Rep. 2025 Jul 1;15(1):21696. doi: 10.1038/s41598-025-05823-2.
10
Quality of Life of Lung Cancer Patients with Immune-Related Endocrinopathies During Immunotherapy: A Prospective Study Based on the EORTC QLQ-C30 and QLQ-LC13 Questionnaires in Romania.免疫治疗期间患有免疫相关内分泌病的肺癌患者的生活质量：一项基于罗马尼亚EORTC QLQ-C30和QLQ-LC13问卷的前瞻性研究。
Curr Oncol. 2025 Jun 5;32(6):332. doi: 10.3390/curroncol32060332.